Clinical Trials Browser

Phase 2 × Colorectal Neoplasms × Specimen Handling × Clear all

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02965703 2026-04-13

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

Phase 2 Active not recruiting

81 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT05223036 2026-04-13

Testing Obeticholic Acid for Familial Adenomatous Polyposis

Phase 2 Suspended

Gastrointestinal

Attenuated familial adenomatous polyposis, Duodenal Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT05419011 2026-04-13

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT06557733 2026-04-13

An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis

Phase 2 Recruiting

Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

NCT07405476 2026-02-12

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04767984 2026-01-21

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Phase 2 Active not recruiting

Gastrointestinal

Colitis, Ulcerative, Colorectal Neoplasms

NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT03396926 2025-02-28

Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer

Phase 2 Completed

44 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT06575725 2024-11-21

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms